Sirona Biochem to Test Novel Antiviral Compounds in Top U.S. Facility

Dec 20, 2021 By MarketDepth

Business COVID-19 Headlines Healthcare Investing What's Hot

Covid19 Vaccine

Sirona Biochem Corp. (TSX-V: SBM) (OTC: SRBCF) announced that its antiviral compounds are set to be tested in a top U.S. facility.

Up Premarket

Shares of Sirona Biochem Corp. (TSX-V: SBM) gained over 12.8% in premarket hours.

Antiviral Compounds

The company’s French subsidiary, TFChem, created a patentable library of 20 compounds designed to target the host cell instead of the COVID-19 virus itself. The antiviral compounds are intended to prevent the cytopathic effect from occurring, through which the COVID-19 virus causes structural changes in the host cell, allowing the virus to replicate and lead to greater damage. 

Tested to Utah State University

The compounds will now be shipped to and tested at the Utah State University’s Institute of Antiviral Research, with the results to be ready in approximately 6 weeks.

“Since the compounds are designed to target the host cell and not the virus itself, we have a unique approach that is based on our proprietary technology. We have seen the number of variants that the SARS-CoV-2 virus has. It will continue to mutate, creating new strains, so there is a strong need for compounds like these that are not targeted to a specific virus.”

Dr. Howard Verrico, CEO of Sirona Biochem.